Pulse.

a daily field guide to health research that matters

◆ Console

‹ Fri · 30 Oct 2026
Standard addition

Comparative Effects of Pharmacological Treatment on Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials.

Several SGLT2 inhibitors and semaglutide reduced hospitalizations for heart failure, though no drug prevented death better than others.

This systematic review and network meta-analysis of randomized trials examined comparative effects of pharmacological treatment on heart failure with mildly reduced or preserved ejection fraction: a systematic review and network meta-analysis of randomized controlled trials. The PubMed abstract reports across 20 randomized trials, no drug-level differences were found for cardiovascular or all-cause mortality, while several sglt2 inhibitors and semaglutide reduced heart-failure hospitalization relative to exenatide.

What the study was

Study design
Systematic review and network meta-analysis of randomized trials
Population
Patients with heart failure with mildly reduced or preserved ejection fraction
Category
Treatment Innovation
Maturity
Validated
Journal
Drugs

Why it surfaced

Score reflects the systematic review and network meta-analysis of randomized trials design and relevance to Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk; classification is limited to PubMed title, metadata, and abstract evidence.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.